Context: Clinical trials are evaluating the efficacy of inhibitors of the myostatin pathway in neuromuscular and metabolic diseases. Activins and follistatins are major regulators of the myostatin pathway, but their physiology in relation to metabolic and anthropometric variables and in response to exercise remains to be fully elucidated in humans.
M
uscle plays a major role in the regulation of energy and glucose homeostasis by adapting its function according to energy intake and physical activity (1) . Chronic exercise is associated with reduced risk for the development of metabolic and cardiovascular diseases (2, 3) . Consequently, research in recent years is focusing on biomolecules that are either secreted by muscle and mediate the effects of exercise at a systemic level or act on muscle tissue and affect its function (4, 5) .
Activin/follistatin (FST)/myostatin-signaling has been identified as an important pathway involved in muscle metabolism, differentiation, and growth (6, 7) . Binding of activins (activin A and activin B) as well as of (the highly homologous to activins) myostatin to activin receptors type II (ActRII) activates a signaling cascade resulting in the inhibition of muscle growth and differentiation (8) . In contrast, follistatins [FST and FST-like 3 (FSTL3)] bind to activins and myostatin to inactivate them, consequently attenuating muscle growth and metabolism (8) . Based on the strong association of activins, myostatin, and FST with muscle function, ongoing phase 2 clinical trials are evaluating the efficacy of ActRII blockers or overexpression of FST in different conditions, ranging from neuromuscular disorders and tumor cachexia to obesity and type 2 diabetes (6, 9, 10) .
Initial results from the use of such medications to treat muscle wasting or atrophy have demonstrated limited efficacy, questioning the translation of the promising findings from animal studies to humans (11) (12) (13) . Given the very limited information about the circulating profile of these hormones in different conditions related to metabolic function in humans, we aimed to investigate: (1) whether and how circulating activin and FSTs concentrations are affected by fitness level, age, parameters of adiposity, and the presence of metabolic syndrome; (2) whether they change during acute exercise; and (3) whether they are affected by the type of exercise performed.
Materials and Methods

Study design
The first study (study 1), an intervention study involving an acute time trial bout of exercise (14) , enrolled 80 healthy men who were recruited and divided into 4 groups (n = 20/group) according to age (young or old) and fitness level (physically active or inactive). The younger participants were between 18 and 35 years of age and the older participants were between 61 and 79 years of age. The physically active individuals had a maximal oxygen uptake (VO 2 max) .35 mL/kg/min among old and .45 mL/kg/min among young participants. These cutoff levels represent the 70th percentile of the population and are considered reasonable for subject classification. Exclusion criteria were: smoking; presence of musculoskeletal, cardiovascular, or respiratory problems; use of antihypertensive medications, supplementation with antioxidant compounds including minerals and vitamins; use of other medications (such as probucol, nebivolol, and anti-inflammatory drugs); and alcohol consumption ,2 weeks before the study. All subjects performed an aerobic exercise including 45 minutes of walking/ running at 70% VO 2 max, followed by 90% of VO 2 max until exhaustion (total exercise time for young inactive. 47. 8 The second study (study 2), an interventional study involving different types of exercise, enrolled 23 sedentary (defined as exercising ,2 h/wk) men aged 30 to 56 years. Participants were divided into metabolically healthy individuals [n = 14; 3 with normal weight, 8 overweight, and 3 obese; i.e., individuals without metabolic syndrome (MetS)] and subjects with MetS (n = 9; 4 overweight and 5 obese) (16) . For MetS, the criteria of the National Heart, Lung, and Blood Association were followed, which demand the presence of at least three of the following: waist circumference .102 cm, fasting blood glucose .100 mg/dL, systolic blood pressure (SBP) $130 mm Hg and/or diastolic blood pressure (DBP) $85 mm Hg, fasting triglycerides $150 mg/dL, and high-density lipoprotein cholesterol ,40 mg/dL. Participants were nonsmokers, had no acute or chronic disease, were not receiving any medication or dietary supplements, and had no recent change in their body weight (defined as weight loss or weight gain of .2 kg within the past 6 months). In a random, crossover design, participants completed four different sessions: resting (no exercise); highintensity interval exercise (HIIE), consisting of 5 3 4 minutes walking on a treadmill at 3 km/h alternating with 4 3 4 minutes running at 90% of the maximum heart rate for a total of 36 minutes; continuous moderate-intensity exercise (MIE), defined as a 36-minute walk/run on a treadmill at 65% of maximum heart rate; and resistance exercise (RE), consisting of 3 sets of 8 to 12 repetitions at 75% to 80% of 1-repetition maximum, which was performed initially for strength assessment. Leg extension, chest press, leg curl, pull down, leg press, and biceps curls were undertaken for ;2 minutes for each set for a total duration of 45 minutes. Subjects had free access to water during the exercise. Blood was obtained 1 hour before the end of the exercise, immediately after, and 1 hour after the completion of each session. The change in plasma volume did not differ significantly among exercise trials or between groups (post-to preexercise ratios; HIIE, 0.97 6 0.09 and 0.96 6 0.03; CME, 1.00 6 0.07 and 1.01 6 0.05; RE, 0.95 6 0.08 and 0.96 6 0.06; for the MetS and healthy groups, respectively). Both studies were in accordance with the Helsinki declaration and were approved by the local institutional review boards. Written informed consent was obtained from all the participants.
Biochemical and body composition measurements
Activin A, activin B, FST, and FSTL3 were measured with ELISA immunoassays from Ansh Laboratories (Webster, TX). The assays had following characteristics: activin A: intra-assay coefficient of variation (CV), 4.25%; interassay CV, 3.83%; sensitivity, 0.065 ng/mL; activin B: intra-assay CV, ,4.1%; interassay, CV ,3.5%; sensitivity, 4.35 pg/mL; FST: intra-assay CV, ,3.59%; interassay CV, ,5.21%; sensitivity, 0.18 ng/mL; FSTL3: intra-assay CV, ,3.5%; interassay CV, ,4.81%; sensitivity, 0.164 ng/mL. Additionally, according to our evaluation, the measured concentrations in all four molecules (activin A, activin B, FST, and FST) remained stable after up to three freeze-thaw cycles (,15% variation). All samples were measured in duplicate and were repeated if coefficient of variation for any sample was .15% (refers to ,5% of the measurements). The value deriving from the repetition was considered the valid one if the CV was ,15%. Plasma glucose, triglycerides, total cholesterol, lactate, and creatine kinase (CK) were measured using an automated analyzer (Hitachi cobas c311; Roche Diagnostics, Indianapolis, IN).
Body fat was assessed by bioelectrical impedance analysis (Bodystat 1500, Limited, Douglas, Isle of Man, UK) in both studies. Lean body mass (LBM) was calculated as body weightfat mass.
Statistical analysis
Statistical analysis was performed with SPSS v19.0 (SPSS, Inc., Chicago, IL) for Windows and with GraphPad prism 7 (GraphPad Software Inc, La Jolla, CA). Data are expressed as means 6 SD unless otherwise stated. Normal distribution of blood parameters was evaluated with Shapiro-Wilk test. Parameters that were not normally distributed were logarithmically transformed. Pearson's correlation coefficients were calculated to correlate hormonal parameters of interest (activins, FST) with anthropometric or other blood parameters in both studies. For comparisons between groups, Student unpaired t test, Wilcoxon signed-rank test, or Mann-Whitney test were used as appropriate. For comparisons in the same group (before and after exercise) paired t test was used. Adjustments for age and fitness level as binary outcomes (i.e., young vs old and physically active vs sedentary, as defined previously), as well as LBM and fat percentage as continuous variables, were performed with analysis of covariance in study 1. For comparison between more than two groups, one-way (for the same time point among the four groups) and three-way ANOVA (for time point, age, and fitness level) for study 1 and three-way ANOVA (for time point, type of exercise, and presence/absence of metabolic syndrome) for study 2 were performed, followed by post hoc test with Bonferroni correction.
Results
Study 1 and study 2: association of circulating activin A, activin B, FST, and FSTL3 with parameters of body composition-adiposity, fitness level, muscle-related proteins, lipidemic profile, and blood pressure Characteristics of the participants from studies 1 and 2 are summarized in Tables 1 and 2 and have been previously published in part (16, 17) . In study 1, older participants, as expected, had higher fat percentage, lower LBM, and higher body mass index (BMI) compared with younger participants. Sedentary participants had higher fat percentage but similar LBM compared with physically active participants. In study 2, the two groups (healthy vs MetS) were, as expected, significantly different in parameters related to MetS [i.e., waist circumference; triglycerides, low-density lipoprotein (LDL), and total cholesterol; glucose; and blood pressure]. They were not significantly different in age or BMI. Healthy subjects had a better fitness level than participants with MetS, indicated by the higher VO 2 max. When combining studies 1 and 2 (Table 3) , circulating activin A and activin B concentrations did not correlate with parameters of body composition-adiposity (i.e., BMI, fat and lean mass and percentage) at baseline (before exercise), whereas circulating levels of these hormones after exercise demonstrate a weak positive association with LBM. In contrast, circulating FST and FSTL3 (pre-and postexercise) correlated strongly and positively with BMI, fat percentage, fat mass, and (except for FSTL3 postexercise) age. The positive correlations of baseline FST and FSTL3 with fat percentage were weaker but still significant after adjusting for age or BMI (FST unadjusted r = 0.499, P , 0.001; adjusted for BMI, r = 0.231, P = 0.029; adjusted for age, r = 0.319, P = 0.002; FSTL3 unadjusted r = 0.513, P , 0.001; adjusted for BMI, r = 0.207, P = 0.051, adjusted for age, r = 0.451, P , 0.001). Similarly, the positive correlations of baseline FST and FSTL3 with BMI and fat mass were weaker but remained significant after adjusting for age (FST with BMI, unadjusted, r = 0.453, P , 0.001; adjusted for age, r = 0.354, P = 0.001; FST with fat mass, unadjusted, r = 0.464, P , 0.001; adjusted for age, r = 0.302, P = 0.004; FSTL3 with BMI, unadjusted, r = 0.491, P , 0.001, adjusted for age, r = 0.431, P , 0.001; FSTL3 with fat mass, unadjusted, r = 0.509, P , 0.001; adjusted for age, r = 0.435, P , 0.004), but did not remain significant after adjusting for fat mass or BMI (most probably because of high collinearity between fat mass and BMI). Additionally, the postexercise activin B concentration was positively associated with VO 2 max, whereas the pre-and postexercise FST concentrations were negatively associated with VO 2 max. FST (before exercise) and FSTL3 (before and after exercise) were also negatively correlated with lactate postexercise. No associations of activins and FST with CK levels were observed, except from a weak positive correlation for activin B and a weak negative for FSTL postexercise with postexercise CK. In study 2, FST levels (pre-and postexercise) were positively associated with total cholesterol, LDL cholesterol, triglycerides, SBP, and DBP. These strong correlations disappeared after adjusting for BMI, fat mass, or fat percentage. When adjusting for LBM, the correlation remained significant between FST and total cholesterol (r = 0.488, P = 0.02), LDL (r = 0.464, P = 0.03), and SBP (r = 0.468, P = 0.028), but not between FST and triglycerides or DBP. Finally, when adjusting for age, the correlation remained significant between FST and total cholesterol (r = 0.494, P = 0.02) and LDL (r = 0.449, P = 0.04). Altogether, the main finding of this analysis is the positive correlation of FST and FSTL3 with parameters of adiposity (i.e., BMI, fat percentage, and fat mass). In contrast, activin A and activin B were not related with these parameters. Specifically, baseline circulating activin A and activin B concentrations were similar between young and old individuals but tended to be higher (P = 0.056 for activin A; P = 0.029 for activin B) in physically active vs sedentary participants (Table 4 ). In contrast, FST and FSTL3 were higher and the activin A/FST ratio lower in older than younger participants (P , 0.001 in all cases). The differences remained significant for FST after adjusting for BMI, fat percentage (consequently lean percentage), LBM, and fat mass (P , 0.01 after all adjustments); and for FSTL3 after adjusting for BMI, fat percentage (consequently also lean percentage), and fat mass (P , 0.01 after all adjustments). Significance for FSTL3 was lost only after adjusting for LBM. FST and FSTL3 were not related to fitness level, indicating that the negative correlation with VO 2 max described for FST previously is due to confounding, most likely by age. Activin A, activin B, FST, and FSTL3 concentrations increased after exercise from ;12% to 21% in the general subject population. The increase after exercise was similar in all subgroups for activin A and FST. On the contrary, there was no increase of activin B after exercise and a smaller increase for FSTL3 in older compared with younger participants. Collectively, the main findings of study 1 are that (1) FST and FSTL3 concentrations are higher in older compared with younger individuals, (2) activin A and activin B tend to be higher in physically active than sedentary individuals, and (3) activin A, activin B, FST, and FSTL3 increase after exercise (except in older individuals, where FSTL3 increases marginally and activin B does not increase at all).
Study 2: changes in circulating levels of activin A, activin B, FST, and FSLT3 in relation to the type of exercise and the presence of MetS In study 2, baseline levels of activin A, activin B, FST, and FSTL3 were similar between metabolically healthy subjects (without MetS) and subjects with MetS (Table  2) . Exercise increased the circulating levels of all hormones (;13% for activin A, ;10% for activin B, and 5% to 10% for FST and FSTL3; Fig. 1 ), which is almost in the same range as observed in the group of old, physically inactive, participants in study 1. All hormones returned to baseline 1 hour after completion of the training session, except for FST, which tended to increase even more. The increase in the hormone concentrations was independent of exercise type, except for MIE and RE, which did not affect the FST and FSTL3 concentrations, respectively. Participants with metabolic syndrome had similar changes in the investigated hormones compared with healthy individuals (Fig. 2) . Altogether, study 2 demonstrates that there are no differences in circulating activins and FSTs between individuals with MetS and healthy controls of similar weight, either before or after exercise.
Discussion
This study investigates together the circulating activin A, activin B, FST, and FSTL3 concentrations at rest and during exercise in populations of different age, fitness level, and metabolic status. We demonstrate here that FST and FSTL3 concentrations are associated positively with parameters of adiposity (i.e., BMI, fat percentage, and fat mass), lipidemic profile (cholesterol, LDL cholesterol, triglycerides), and blood pressure. Moreover, FST and FSTL3 concentrations were higher in older than younger individuals independently of fitness level and several parameters of body composition, whereas activin A and activin B tended to be higher in physically active individuals independently of age. Additionally, we demonstrate that acute exercise increases the concentrations of all four hormones in the circulation by ;10% to 21%. This increase is attenuated for activin B and is lower for FSTL3 in older individuals. The increase of the activin and FST concentrations during exercise is largely independent of exercise type and of the presence of MetS.
Changes in activins and FSTs do not point to an upregulation of the myostatin pathway with aging or in subjects with MetS Activins and FSTs are secreted by gonads (i.e., testis, Sertoli and Leydig cells, ovary and follicles) and other organs, such as the skeletal muscle, adipose tissue, and pancreas (8, 18) . Additionally, the liver contributes significantly to the concentrations of FST and activin A in the circulation, which are thus associated with liver diseases (19) (20) (21) (22) . The lack of robust associations of activin A and activin B with parameters of adiposity in our study indicates that the concentrations of these hormones do not reflect the musculoskeletal, fat, or metabolic status. In contrast, the positive association of FST and FSTL3 with parameters of adiposity indicates possible contribution of the adipose tissue in the circulating profile of these hormones. This is further supported by the positive correlation of FST and FSTL3 with cholesterol, LDL cholesterol, triglycerides, and blood pressure that is lost after adjusting for fat mass. Additionally, FST and FSTL3 increase with age, whereas activin A and activin B do not change. Altogether, the changes we observed do not point to an upregulation of the myostatin pathway (e.g., through an upregulation of activins or downregulation of FST) in participants of older age or with MetS, but rather to a downregulation of it (i.e., through higher FST with unchanged activins). Thus, it is unlikely that the studied members contribute significantly to the loss of muscle mass observed with aging or to the dysfunction of glucose and lipid homeostasis in people with MetS through an upregulation of the myostatin pathway. In contrast, the changes found may serve as a compensatory mechanism aiming at preserving or increasing muscle mass in conditions of metabolic dysfunction to achieve a metabolic benefit.
Activins and FSTs increase after exercise similarly in individuals with and without MetS
Muscle metabolism is also significantly affected by exercise. As we demonstrate in the current study, exercise acutely increased the concentrations of both activins and FST in the circulation. Given the lack of a correlation of activin A, FST, or FSTL3 with CK postexercise, the increase of the concentrations of these hormones after exercise is probably not deriving from muscle fiber damage. Additionally, the increase after exercise was largely independent of exercise type, with the exception of moderate-intensity exercise, which did not affect FST, and resistance exercise, which did not change FSTL3. Previous studies have also demonstrated an increase of FST after acute or chronic exercise (19, (23) (24) (25) (26) , whereas, to our knowledge, activin A, activin B, and FSTL3 have not been previously investigated in response to acute exercise. In our study, the concentrations of all studied hormones returned to baseline 1 hour after completion of exercise with the exception of FST. Hansen et al. have reported that the circulating FST concentrations remain stable during the first 2 hours of exercise and increase up to fivefold during the first 2 hours of recovery in response to an altered glucagon-to-insulin ratio (19, 24) . In our study, FST was assessed directly after exercise sessions that lasted approximately 1 hour, in study 1, and ;45 to 55 minutes, in study 2, as well as 1 hour after recovery in study 2, and its concentration increased by 10% to 20%. Because, 1 hour after recovery, FST had not returned to baseline, we cannot exclude a further increase during recovery. The lack of changes in activin B and the limited increase of FSTL3 by exercise in old participants may indicate differences in acute secretion mechanisms for these hormones, compared with activin A and FST. Given that activin B and FSTL3 are not secreted by the liver (as are activin A and FST), their main source in the circulation remains the gonads, whose function is especially susceptible to aging. Finally, the lack of substantial differences in the circulating profile of any of the investigated hormones during exercise between individuals with and individuals without MetS is an additional argument against an important alteration of the myostatin pathway through these hormones in metabolic abnormalities. We did not perform myostatin measurements herein. Myostatin is primarily secreted by muscle tissue, and most previous reports have shown a repression of the myostatin gene in muscle during exercise. However, other studies, including one from our group, did not observe a similar reduction of circulating myostatin during exercise (7, 17, (27) (28) (29) (30) (31) (32) (33) . Limitations of our study include the lack of muscle biopsies to evaluate ActRII expression or the myostatin signaling cascade, which would make the study more invasive, the recruitment of male participants only, and the relatively small, albeit adequately powered, sample size of study 2.
Clinical importance of the current findings
Several ongoing phase 2 clinical trials are investigating the efficacy of ActRII blockers in diseases affecting muscle function or muscle mass. The concept supporting these studies is that treatment with ActRII blockers will downregulate the activin-myostatin/FST pathway and result in muscle differentiation and growth. The expectation for such effects derives, in most cases, from highly promising results from animal studies. However, as has been recently demonstrated for neuromuscular diseases, the activin/FST/myostatin pathway may have already been shut down through endogenous adaptive mechanisms (12) . In that case, further blocking it will have only marginal effects. In our study, we observed higher FST and FSTL3 levels in older people, with a similar circulating profile of activins and FST at rest and after exercise in people with and without MetS, as well as positive correlations of FST and FSTL3 with components of the MetS (triglycerides, blood pressure) resulting from increased fat mass. Thus, treatment with ActRII blockers in these conditions will most probably interfere with either an already downregulated or normally functioning signaling pathway. Consequently, the efficacy of such https://academic.oup.com/jcemtreatments may be limited, whereas, in contrast, important functions of activins and FST in other systems [e.g., the reproductive system (34)] may be affected. Consistent with this assertion, a recent study demonstrated a rather modest improvement of LBM (2.7%) and no changes in body weight in overweight or obese individuals with insulin resistance who were treated with the ActRII-blocker bimagrumab (10) .
Conclusion
Collectively, our study provides important insights about the physiology of activins and FST in relation to metabolic status, exercise, fitness level, and age. Our findings may also inform study design for future trials and demonstrate the need for careful assessment of patient eligibility in future trials with drugs targeting the activin/FST/myostatin pathway.
